RosenheckRPerlickDBinghamSEffectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA. 2003;290(20):2693–2702.
4.
KeefeRSESeidmanLJChristensenBKComparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry. 2004;161:985–995.
5.
RosenheckRA. Effectiveness versus efficacy of second-generation antipsychotics: Haloperidol without anticholinergics as a comparator. Psychiatr Serv. 2005;56(1):85–92.
6.
LiebermanJAStroupSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223.
7.
RelmanAS. 2003 Nov 18. Your doctor's drug problem. The New York Times.
8.
SchulzK.Did antidepressants depress Japan? The New York Times. 2004 Aug 22.
9.
ProcyshynRMChauAFortinPPrevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine. Can J Psychiatry. 2004;49(9):601–606.
10.
Cantor-GraaeE.The contribution of social factors to the development of schizophrenia: A review of recent findings. Can J Psychiatry2007;52:277–286.
11.
JarvisGE. The social causes of psychosis in North American psychiatry: A review of a disappearing literature. Can J Psychiatry2007;52:287–294.
12.
Cantor-GraaeESeltenJP. Schizophrenia and migration: A meta-analysis and review. Am J Psychiatry. 2005;162:12–24.
13.
KirkbrideJBFearonPMorganCHeterogeneity in incidence rates of schizophrenia and other psychotic syndromes: Findings from the 3-center AESOP study. Arch Gen Psychiatry. 2006;63:250–258.
14.
VelingWSeltenJ-PVeenNIncidence of schizophrenia among ethnic minorities in the Netherlands: A four-year first-contact study. Schizophr Res. 2006;86:189–193.